Cilengitide

Drug Profile

Cilengitide

Alternative Names: Cilcane; EMD-121974; EMD-85189; ICE1

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Merck KGaA; The Scripps Research Institute; University of Munich
  • Developer Iceni Pharmaceuticals; Martin Luther University of Halle-Wittenberg; Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics; Cyclic peptides; Small molecules; Venoms
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • Discontinued Glioblastoma; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 25 May 2016 Preclinical trials in Multiple myeloma in United Kingdom (unspecified route)
  • 25 May 2016 Iceni Pharmaceuticals plans a phase II trial for Multiple myeloma (Combination therapy, Late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top